INS and metabolic syndrome: Similar to CTRP1, circulating FGF21 levels in subjects with T2DM were also unexpectedly higher compared to those of healthy subjects, although the administration of recombinant FGF21 in obese and diabetic rodent models ameliorates hyperglycemia and dyslipidemia by the enhancement of insulin sensitivity and glucose uptake [21].